benzyl [2-(4-hydroxy-phenyl)-1,1-dimethyl-ethyl]-carbamate | 868049-78-9

• 英文名称: benzyl [2-(4-hydroxy-phenyl)-1,1-dimethyl-ethyl]-carbamate
• 英文别名: benzyl N-[1-(4-hydroxyphenyl)-2-methylpropan-2-yl]carbamate
• CAS: 868049-78-9
• 化学式: C₁₈H₂₁NO₃
• 分子量: 299.37
• InChiKey: WNULYKWIGSZELF-UHFFFAOYSA-N

物化性质

• 沸点：
  489.2±38.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl [2-(4-hydroxy-phenyl)-1,1-dimethyl-ethyl]-carbamate 、 碘甲烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-[N-(苄氧羰基)氨基]-1,1-二甲基-2-(4-甲氧基苯基)乙烷
  参考文献：
  名称：

  Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy

  摘要：

  Compound 4p was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human beta(2)-adrenoceptor with a high beta(1)/beta(2)-selectivity. A complete reversal of acetylcholine-induced bronchoconstriction which lasted over the whole study period of 5 h was demonstrated for 4p in a guinea pig in vivo model without any signs of cardiovascular effects up to 10-fold above the first dose reaching 100% bronchoprotection. The enantiomerically pure (R)-form of 4p exerted a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects. Formoterol which was tested as comparator in the same in vivo models of acetylcholine-induced bronchoconstriction did not retain efficacy after 24 h. In summary, the preclinical pro. le of compound (R)-4p (olodaterol, also known as BI 1744 CL) suggests a potential for once-daily dosing in man accompanied with an improved safety pro. le. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.087
• 作为产物：
  描述：

  4-(2-氨基-2-甲基丙基)苯酚 、 氯甲酸苄酯 在 sodium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 benzyl [2-(4-hydroxy-phenyl)-1,1-dimethyl-ethyl]-carbamate
  参考文献：
  名称：

  Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy

  摘要：

  Compound 4p was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human beta(2)-adrenoceptor with a high beta(1)/beta(2)-selectivity. A complete reversal of acetylcholine-induced bronchoconstriction which lasted over the whole study period of 5 h was demonstrated for 4p in a guinea pig in vivo model without any signs of cardiovascular effects up to 10-fold above the first dose reaching 100% bronchoprotection. The enantiomerically pure (R)-form of 4p exerted a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects. Formoterol which was tested as comparator in the same in vivo models of acetylcholine-induced bronchoconstriction did not retain efficacy after 24 h. In summary, the preclinical pro. le of compound (R)-4p (olodaterol, also known as BI 1744 CL) suggests a potential for once-daily dosing in man accompanied with an improved safety pro. le. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.087

文献信息

• Aerosol formulation for the inhalation of beta-agonists
  申请人：Aven Michael

  公开号：US20050256115A1

  公开（公告）日：2005-11-17

  The present invention relates to a propellant-free aerosol formulation which [contains] one or more compounds of general formula 1 wherein the groups R 1 , R 2 , R 3 and X − may have the meanings given in the claims and specification, for inhalation.

  本发明涉及一种无推进剂的气雾剂配方，其中包含一个或多个一般式1中的化合物，其中基团R1、R2、R3和X−可能具有索赔和说明中给定的含义，用于吸入。
• Novel medicament combinations for the treatment of respiratory diseases
  申请人：Konetzki Ingo

  公开号：US20050239778A1

  公开（公告）日：2005-10-27

  The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups R 1 , R 2 and R 3 may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

  本发明涉及一种新的药物组合物，除了含有一个或多个通常为一个的一般式1中的化合物，其中基团R1、R2和R3可能具有申请中所给出的含义和说明中的含义，还含有至少一种其他活性物质2，以及制备它们的方法和它们作为药用组合物的用途。
• Novel medicaments for the treatment of respiratory diseases
  申请人：Konetzki Ingo

  公开号：US20050272726A1

  公开（公告）日：2005-12-08

  The present invention relates to the use of the compounds of general formula 1 wherein the groups R 1 , R 2 and R 3 may have the meanings given in the claims and in the specification, for preparing a pharmaceutical composition for the treatment of respiratory complaints.

  本发明涉及使用一般式1中的化合物，其中基团R1、R2和R3可能具有权利要求和说明书中给定的含义，用于制备用于治疗呼吸道疾病的药物组合物。
• AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS
  申请人：AVEN Michael

  公开号：US20120035169A1

  公开（公告）日：2012-02-09

  The present invention relates to a propellant-free aerosol formulation which [contains] one or more compounds of general formula 1 wherein the groups R 1 , R 2 , R 3 and X − may have the meanings given in the claims and specification, for inhalation.

  本发明涉及一种无推进剂的气雾剂配方，其中包含一种或多种一般式1的化合物，其中基团R1、R2、R3和X-可以具有在权利要求书和说明书中给出的含义，用于吸入。
• NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES
  申请人：KONETZKI Ingo

  公开号：US20090181961A1

  公开（公告）日：2009-07-16

  The present invention relates to the use of the compounds of general formula 1 wherein the groups R 1 , R 2 and R 3 may have the meanings given in the claims and in the specification, for preparing a pharmaceutical composition for the treatment of respiratory complaints.

  本发明涉及使用一般式1中的化合物，其中基团R1、R2和R3可以具有在权利要求和说明书中给出的含义，用于制备治疗呼吸道疾病的药物组合物。